Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5354 - GSTP1 c.313A>G, XPD c.934G>A, XPF c.2505T>C and CASP9 c.-1339A>G polymorphisms and severity of vomiting in head and neck cancer patients treated with cisplatin Chemoradiation

Date

10 Sep 2017

Session

Poster display session

Presenters

Carmen Passos Lima

Citation

Annals of Oncology (2017) 28 (suppl_5): v372-v394. 10.1093/annonc/mdx374

Authors

C.S.P. Passos Lima, J. Carron, L. Lopes-Aguiar, E.F.D. Costa, G.A.S. Nogueira, T.R.P. Lima, E.C. Pincinato, M.B. Visacri, J.C.F. Quintanilha, P. Moriel, G.J. Lourenço

Author affiliations

  • Department Of Internal Medicine, University of Campinas, 13083-970 - Campinas/BR
More

Resources

Abstract 5354

Background

Cisplatin (CDDP) chemotherapy associated with radiation (RT) has been used in head and neck squamous cell carcinoma (HNSCC) patients, and vomiting is a common side effect during treatment. This prospective study aimed to identify the roles of GSTM1 and GSTT1 (presents or nulls), GSTP1 c.313A>G, XPC c.2815A>C, XPD c.934G>A and c.2251A>C, XPF c.2505T>C, ERCC1 c.354C>T, MLH1 c.−93G>A, MSH2 c.211 + 9C>G, MSH3 c.3133G>A, EXO1 c.1765G>A, TP53 c.215G>C, CASP3 c.-1191A>G and c.-1168G>T, CASP9 c.-1339A>G, CASP8 c.-937_-932delAGTAAG, FAS c.-1378G>A and c.-671A>G, and FASL c.-157-687C>T single nucleotide polymorphisms, involved in CDDP metabolism, in vomiting severity in HNSCC patients treated with CDDP and RT.

Methods

We evaluated 88 HNSCC patients diagnosed June 2011-February 2014 which receive CDDP chemoradiation. Ondansetron and dexamethasone were administered as antiemetic therapy and evaluated using National Cancer Institute criteria. Genotypes were analyzed in genomic DNA by polymerase chain reaction based methods. The logistic regression model was used to identify variables influencing toxicities and significant results were validated using a bootstrap (bt) resampling to investigate the stability of risk estimates (1000 replications).

Results

GSTP1 c.313AG or GG genotype alone (46.7% vs 18.6%, P = 0.004) and combined with XPD c.934GA or AA (50.0% vs 16.7%, P = 0.02; Pbt= 0.008), XPF c.2505TC or CC (52.2% vs 16.7%, P = 0.02; Pbt= 0.007) and CASP9 c.-1339AG or GG (51.9% vs 16.7%, P = 0.02; Pbt= 0.01) genotypes were more common in patients with moderate/severe vomiting than other genotypes. Carries with GSTP1 c.313AG or GG genotypes alone and combined with XPD c.934GA or AA, XPF c.2505TC or CC and CASP9 c.-1339AG or GG genotypes had 4.28, 5.00, 5.45, and 5.38 more chances of presenting moderate/severe vomiting than others.

Conclusions

Our data suggest, for the first time, that inherited abnormalities in DNA repair and apoptosis pathways are capable of modulating emesis in HNSCC patients under CDDP chemoradiation, and may be used for selecting patients who deserve to receive distinct doses of antiemetics or association of potent antiemetics in clinical practice.

Clinical trial identification

Legal entity responsible for the study

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.